High Human IgG Levels in Severe Combined Immunodeficient Mouse Reconstituted with Human Splenic Tissues from Patients with Gastric Cancer

Tetsuro Kubota, Hiroshi Yamaguchi, Masahiko Watanabe, Takaaki Yamamoto, Tetsuya Takahara, Tooru Takeuchi, Toshiharu Furukawa, Suguru Kase, Susumu Kodaira, Kyuya Ishibiki, Masaki Kitajima

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We implanted normal peripheral blood lymphocytes (PBL) from healthy donors and splenic tissues from patients with gastric cancers into the severe combined immunodeficient (SCID) mouse, demonstrating that SCID mouse with splenic tissue can produce a high level of human immuno‐globulin G (IgG). The normal PBLs at 107 and 108/mouse were implanted intraperitoneally, and three splenic tissues with a size of 3×3×3 mm from gastric cancer patients were inoculated subcutaneously into the bilateral backs of the mice. At 2, 4, 6 and 8 weeks after inoculation, mice were killed, and the human IgG was assessed by an ELISA method. SCID mice with splenic tissue revealed high human IgG levels from 2 weeks after inoculation and approximately 2 mg of IgG per ml was observed at 8 weeks post‐implantation, while the IgG levels in mice treated with PBLs were limited. Since the half life of the extrinsic human IgG was 10.2 days, the high level of human IgG in the SCID mice was supposed to be produced by human plasma cells in the splenic tissue from gastric cancer patients. This model was thought to be adequate for evaluating human immunological functions in vivo.

Original languageEnglish
Pages (from-to)300-303
Number of pages4
JournalJapanese Journal of Cancer Research
Volume83
Issue number3
DOIs
Publication statusPublished - 1992 Mar

Keywords

  • Human immunoglobulin
  • Key words
  • SCID mouse
  • Splenic tissue

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'High Human IgG Levels in Severe Combined Immunodeficient Mouse Reconstituted with Human Splenic Tissues from Patients with Gastric Cancer'. Together they form a unique fingerprint.

Cite this